Customer concentration and order volatility
A single customer represented 10% or more of total net revenue in multiple years; reduced orders or deferrals could materially impact results.
- Scope
- Revenue concentration
- Materiality
- high
Accuray Incorporated
Accuray Incorporated is a radiation therapy company that develops, manufactures, sells, and supports systems used to deliver highly precise radiation treatments. Its core platforms—CyberKnife and TomoTherapy (including Radixact)—combine treatment delivery hardware with planning and data management software to treat complex cases and streamline more routine cases. The business model is built around capital equipment sales with long, variable sales and installation cycles, supplemented by recurring service, upgrades, and software-related revenue. Accuray sells globally through a mix of direct sales (notably in the U.S. and key international markets) and distributors, with revenue reported across the Americas, EIMEA, Japan, China, and Asia Pacific.
−4,6 %
27,7 %
−12,2 %
−12,3 %
1.50
0.74
| % | |
|---|---|
| Radiation therapy platforms (CyberKnife & TomoTherapy/Radixact) | 55% Capital sales of radiation treatment systems including delivery hardware and associated system components. |
| Service and support | 30% Recurring service plans and support activities including maintenance, warranty, and field service for the installed base. |
| Upgrades and enhancements | 10% Hardware and software upgrades, enhancements, and simplifications sold to existing customers to extend system capability and life. |
| Software (planning and data management) | 5% Treatment planning and data management software, including capitalized software developed for sale. |
Accuray primarily sells to hospitals, cancer treatment centers, and stand-alone radiation therapy facilities that...
- Hospitals and integrated delivery networksprimary
Buy platforms plus multi-year service to expand/upgrade radiation oncology capabilities and standardize across sites.
- Cancer treatment centers and stand-alone clinicsprimary
Purchase CyberKnife/TomoTherapy systems and upgrades to differentiate on precision, throughput, and treatment flexibility.
- Government and public-sector healthcare providerssecondary
Procure systems through tenders and formal purchasing processes; timing depends on budgets, approvals, and site readiness.
- Distributors/agents (indirect channel)secondary
Resell into markets where Accuray relies on local coverage, regulatory navigation, and tender participation.
- Academic and research institutionsemerging
Collaborate on research programs and clinical studies that support new indications, evidence generation, and adoption.
Accuray reports revenue across five regions: the Americas, EIMEA, Japan, China, and Asia Pacific, reflecting a globally...
- •Five reporting regions: Americas, EIMEA, Japan, China, Asia Pacific
- •EIMEA is a major revenue contributor and spans Europe/India/MEA
- •China is a large revenue region, affecting collections and timing
- •Direct U.S. selling supplemented by agents and GPO relationships
- •International offices: Switzerland, Hong Kong, Shanghai, Tokyo
- •Distributors used across EMEA, APAC, Latin America and others
- •FX fluctuations can affect backlog conversion and reported revenue
Accuray’s strategy centers on advancing and simplifying its CyberKnife and TomoTherapy/Radixact platforms while...
01
Improve backlog conversion and reduce volatility from long cyclesshort-term
Revenue recognition depends on site readiness and installation timing, making forecasting and cash flow sensitive to delays and cancellations.
02
Sustain innovation through upgrades, enhancements, and simplificationmedium-term
Platform competitiveness depends on clinical performance, usability, and the ability to launch enhancements on time and at controlled cost.
03
Scale global commercial coverage via direct and distributor channelsmedium-term
International growth relies on local market access, tender participation, and regulatory approvals, supported by offices and distributors.
Accuray’s revenue is exposed to long and variable sales and installation cycles for CyberKnife and TomoTherapy systems,...
Backlog conversion and long installation cycle
Time from first contact to backlog-qualifying contract can be 6–30 months and revenue recognition depends on customer room preparation; cancellations and delays are hard to forecast.
- Scope
- Revenue timing and cash flow
- Materiality
- high
Regulatory approval and compliance risk
Upgrades, modifications, and new indications may require FDA 510(k) or other approvals; failure to obtain/maintain approvals prevents marketing and sales in affected countries.
- Scope
- Market access
- Materiality
- high
Cybersecurity and sensitive data protection
The company regularly experiences cybersecurity incidents and relies on third parties; breaches could disrupt operations and compromise sensitive information/PHI.
- Scope
- Operational disruption and legal/regulatory
- Materiality
- medium
Intellectual property enforcement and litigation
IP is difficult and costly to protect; adverse outcomes in infringement disputes could disrupt component supply or prevent sales of products/components.
- Scope
- Product continuity and legal costs
- Materiality
- medium
Revenue recognition and stand-alone selling price (SSP)
Inventory valuation and excess/obsolete reserves
: 11/08/2026